You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
|
|---|---|
| Published in |
Journal of Hematology & Oncology, April 2023
|
| DOI | 10.1186/s13045-023-01435-3 |
| Pubmed ID | |
| Authors |
Ruihao Huang, Qin Wen, Xi Zhang |
| Abstract |
Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 15% |
| Mexico | 1 | 8% |
| India | 1 | 8% |
| Saudi Arabia | 1 | 8% |
| Unknown | 8 | 62% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 62% |
| Scientists | 3 | 23% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 14% |
| Student > Ph. D. Student | 2 | 9% |
| Unspecified | 2 | 9% |
| Student > Doctoral Student | 2 | 9% |
| Student > Bachelor | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 12 | 55% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 2 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 9% |
| Engineering | 2 | 9% |
| Agricultural and Biological Sciences | 1 | 5% |
| Medicine and Dentistry | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 13 | 59% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2023.
All research outputs
#2,006,405
of 25,171,799 outputs
Outputs from Journal of Hematology & Oncology
#164
of 1,282 outputs
Outputs of similar age
#39,357
of 409,638 outputs
Outputs of similar age from Journal of Hematology & Oncology
#6
of 29 outputs
Altmetric has tracked 25,171,799 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,282 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 409,638 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.